BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: Role of antiviral prophylaxis. World J Gastroenterol 2013; 19(9): 1342-1348 [PMID: 23538480 DOI: 10.3748/wjg.v19.i9.1342] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Fang J, Li W, Tan M, Chen W, Zhang C, Wang W, Xu Q, Guo X. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation. Int Urol Nephrol 2018;50:1653-60. [PMID: 29644524 DOI: 10.1007/s11255-018-1867-0] [Reference Citation Analysis]
2 Vilarrasa E, Puig L. Psoriasis: Biologic treatment and liver disease. World J Dermatol 2014; 3(4): 76-85 [DOI: 10.5314/wjd.v3.i4.76] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Yamamoto-Furusho JK, Bosques-Padilla F, Daffra P, De Paula JA, Etchevers J, Galiano MT, Ibañez P, Juliao F, Kotze PG, Marroquín de la Garza JM, Monreal Robles R, Rocha JL, Steinwurz F, Vázquez-Frías R, Veitia G, Zaltman C. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Rev Gastroenterol Mex 2017;82:134-55. [PMID: 28318706 DOI: 10.1016/j.rgmx.2016.07.005] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Fang J, Li W, Tan M, Peng X, Tan Z, Wang W. Effect of different hepatitis B infection status on the prognosis of active lupus nephritis treated with immunosuppression: a retrospective analysis of 177 patients. Int J Rheum Dis 2018;21:1060-7. [PMID: 29878614 DOI: 10.1111/1756-185X.13313] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Luck ME, Muljo SA, Collins CB. Prospects for Therapeutic Targeting of MicroRNAs in Human Immunological Diseases. J Immunol. 2015;194:5047-5052. [PMID: 25980029 DOI: 10.4049/jimmunol.1403146] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
6 Chang JY, Jung SA, Moon CM, Kim SE, Jung HK, Shim KN. Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea. Intest Res 2018;16:599-608. [PMID: 30301330 DOI: 10.5217/ir.2018.00012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Grigas J, Montoya M, Simkute E, Buitkus M, Zagrabskaite R, Pautienius A, Razukevicius D, Jonaitis LV, Kiudelis G, Skieceviciene J, Vaiciuniene R, Stankuviene A, Bumblyte IA, Kupcinskas J, Stankevicius A. Molecular Characterization and Seroprevalence of Hepatitis E Virus in Inflammatory Bowel Disease Patients and Solid Organ Transplant Recipients. Viruses 2021;13:670. [PMID: 33924409 DOI: 10.3390/v13040670] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3516-3524 [PMID: 24707134 DOI: 10.3748/wjg.v20.i13.3516] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
9 Cheung MC, Agarwal K. Liver abnormalities in the immunosuppressed. Best Practice & Research Clinical Gastroenterology 2013;27:597-618. [DOI: 10.1016/j.bpg.2013.06.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication). Intest Res 2018;16:178-93. [PMID: 29743831 DOI: 10.5217/ir.2018.16.2.178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
11 Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol 2016; 22(28): 6444-6455 [PMID: 27605880 DOI: 10.3748/wjg.v22.i28.6444] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
12 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1014] [Article Influence: 153.7] [Reference Citation Analysis]
13 Fang J, Li W, Peng X, Tan Z, Tan M, Zhang C, Wang W, Xu Z, Zhou G. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis. Int Urol Nephrol 2017;49:475-82. [PMID: 28032257 DOI: 10.1007/s11255-016-1487-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
14 Suzuki K, Kumagai I, Yoshida Y, Miyasaka A, Takikawa Y, Kamiya R, Kondo K, Kato A, Chiba T, Okamoto H. Asymptomatic acute hepatitis E in a female patient with ulcerative colitis. Clin J Gastroenterol 2017;10:255-60. [PMID: 28353200 DOI: 10.1007/s12328-017-0730-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
15 López-Serrano P, Briongos ELF, Alonso EC, Pérez-Calle JL, Rodríguez CF. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol 2015; 7(3): 539-547 [PMID: 25848477 DOI: 10.4254/wjh.v7.i3.539] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
16 Cordero-Coma M, Salazar-Méndez R, Yilmaz T. Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues. Expert Opin Drug Saf 2015;14:1353-71. [PMID: 26118392 DOI: 10.1517/14740338.2015.1061992] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Nguyen DL, Nguyen ET, Bechtold ML. Effect of Immunosuppressive Therapies for the Treatment of Inflammatory Bowel Disease on Response to Routine Vaccinations: A Meta-Analysis. Dig Dis Sci 2015;60:2446-53. [PMID: 25796579 DOI: 10.1007/s10620-015-3631-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
18 Ben Musa R, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S, Shapiro D, Mutlu E. Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(41): 15358-15366 [PMID: 25386085 DOI: 10.3748/wjg.v20.i41.15358] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
19 Chebli JM, Gaburri PD, Chebli LA, da Rocha Ribeiro TC, Pinto AL, Ambrogini Júnior O, Damião AO. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit 2014;20:487-98. [PMID: 24667275 DOI: 10.12659/MSM.890331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]